Funding for this research was provided by:
Universitätsklinikum Ulm
Article History
Received: 10 May 2022
Accepted: 9 June 2022
First Online: 18 June 2022
Declarations
:
: UD and FG do not report any conflict of interest. CDS reports grants, personal fees from AstraZeneca, individual fees and non-financial support from BBraun Melsungen, personal fees from BioNtech, grants, personal fees and non-financial support from Gilead Sciences, grants and personal fees from Janssen-Cilag, personal fees from Eli Lilly, personal fees from Formycon, personal fees from Roche, other from Apeiron, grants and personal fees from MSD, grants from Cepheid, personal fees from GSK, personal fees from Molecular partners, other from Eli Lilly, personal fees from SOBI during the conduct of the study; personal fees from AbbVie, personal fees from MSD, personal fees from Synairgen, grants and personal fees from ViiV Healthcare, outside the submitted work.
: According to local law, no ethics committee statement had to be obtained, as only anonymized publicly available data have been processed.